11-Sep-2026
TipRanks (Tue, 8-Sep 3:45 PM ET)
TipRanks (Tue, 8-Sep 12:35 PM ET)
Biggest stock movers Tuesday: ZIM, NVS, quantum computing stocks, and more
Seeking Alpha News (Tue, 8-Sep 9:42 AM ET)
Business Wire (Tue, 8-Sep 9:00 AM ET)
Biggest stock movers Tuesday: ZIM, NVS, and more
Seeking Alpha News (Tue, 8-Sep 5:23 AM ET)
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
Seeking Alpha News (Tue, 8-Sep 4:56 AM ET)
PRNewswire (Fri, 4-Sep 10:01 PM ET)
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire (Mon, 31-Aug 4:30 PM ET)
Business Wire (Wed, 5-Aug 4:05 PM ET)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 29-Jul 5:00 PM ET)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of September 11, 2026, SRPT stock price declined to $20.45 with 1,585,774 million shares trading.
SRPT has a beta of 2.21, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.15 to the broad based SPY ETF.
SRPT has a market cap of $2.16 billion. This is considered a Mid Cap stock.
Last quarter Sarepta Therapeutics reported $401 million in Revenue and $.64 earnings per share. This beat revenue expectation by $37 million and exceeded earnings estimates by $.18.
In the last 3 years, SRPT traded as high as $173.25 and as low as $10.42.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): FBT, XBI, VTI, VB, SPSM.
SRPT has underperformed the market in the last year with a price return of +14.2% while the SPY ETF gained +17.4%. However, in the short term, SRPT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +36.3% vs +3.9% return in SPY. But in the last 2 weeks, SRPT shares have been beat by the market, returning -2.0% compared to an SPY return of -0.7%.
SRPT support price is $19.53 and resistance is $21.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.